PubRank

S Kochanek

Author PubWeight™ 42.36‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998 2.65
2 Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci U S A 1999 2.41
3 Frequency and stability of chromosomal integration of adenovirus vectors. J Virol 1999 2.18
4 Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci U S A 2000 2.05
5 Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci U S A 1995 1.81
6 An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci U S A 1998 1.76
7 Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci U S A 1999 1.72
8 High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther 1998 1.67
9 Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci U S A 1997 1.52
10 Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. Hum Gene Ther 2000 1.47
11 Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum Gene Ther 2001 1.41
12 In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther 1996 1.37
13 Eukaryotic DNA methylation: facts and problems. FEBS Lett 1990 1.34
14 Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999 1.22
15 Adenovirus type 2 VAI RNA transcription by polymerase III is blocked by sequence-specific methylation. J Virol 1991 1.06
16 Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol Med 2000 1.05
17 Comparison of long-term transgene expression after non-viral and adenoviral gene transfer into primary articular chondrocytes. Histochem Cell Biol 2001 0.95
18 DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. Hum Gene Ther 1999 0.94
19 Viral gene delivery to skeletal muscle: insights on maturation-dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. Hum Gene Ther 1997 0.94
20 Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles. Gene Ther 1998 0.92
21 Interleukin-12 inhibits liver-specific drug-inducible systems in vivo. Gene Ther 2007 0.90
22 Fetal muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity adenoviral vectors. Gene Ther 2003 0.89
23 CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle. Gene Ther 2004 0.88
24 An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood. Gene Ther 2010 0.88
25 Adenovirus vectors: biology, design, and production. Curr Top Microbiol Immunol 2004 0.87
26 Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero. Gene Ther 2005 0.86
27 Hemangiopericytoma of meninges. II. General and clinical data. Zentralbl Neurochir 1986 0.85
28 Targeting of high-capacity adenoviral vectors. Hum Gene Ther 2001 0.85
29 Local high-capacity adenovirus-mediated mCTLA4Ig and mCD40Ig expression prolongs recombinant gene expression in skeletal muscle. Mol Ther 2001 0.84
30 Foamy virus--adenovirus hybrid vectors. Gene Ther 2004 0.82
31 Neural precursor cells as carriers for a gene therapeutical approach in tumor therapy. Cell Transplant 2003 0.81
32 Hemangiopericytoma of meninges. I. Histopathological variability and differential diagnosis. Zentralbl Neurochir 1986 0.81
33 Iris pigment epithelial cells: a possible cell source for the future treatment of neurodegenerative diseases. Exp Neurol 2004 0.78
34 Genetic aspects and research development in haemostasis. Haemophilia 2008 0.75
35 Intracerebral transplantation and successful integration of astrocytes following genetic modification with a high-capacity adenoviral vector. Cell Transplant 2002 0.75